September Newsdesk

Bringing you the latest news on herpes research and events from around the world

Late Breaking Story Late Breaking Story Late Breaking Story Late Breaking Story Late Breaking Story

Millions of people with herpes & their partners set to benefit from drug breakthrough
US regulators have approved Valtrex (valaciclovir) for suppressive therapy to reduce the risk of heterosexual transmission of genital herpes. Valtrex is the first and only drug proven to reduce the transmission of symptomatic signs of a sexually transmitted infection from a person with herpes to their sexual partner. Accordingly, this recent FDA approval has been hailed as an important advance in herpes management as it brings physical and emotional benefits to millions of people with herpes and their partners.
[View full article]

International Herpes Week 2003 Plans Unveiled
Plans for a high profile International Herpes Week (IHW) 2003, running between the 16th-22nd
November 2003 have been released. This is the fourth year for this annual initiative and IHW
has become a firm fixture on the international health calendar attracting worldwide media and
patient interest.
[View full article]

HSV-1 emerges as main cause of recurrent genital ulcerative disease in women in Northern Ireland
HSV-1, classically associated with cold sores, is increasingly being recognised as the cause of
genital herpes. A recent study in Belfast confirms that this trend is observed in Ireland too.
[View full article]

Adolescent Vaccination Against Herpes By The End Of The Decade?
In a step considered to signal the imminent prospect of adolescent vaccines, the US Centers for Disease Control and Prevention has appointed a sub-committee on adolescent immunization.
The group will consider how to integrate new vaccines into the program and whether they should
be recommended for all youngsters.
[View full article]